LAG3 and glioblastoma: In the context of GBM, two phase I clinical trials (NCT02658981 and NCT03493932) are underway to explore the antitumor effect of the LAG-3 inhibitor relatlimab (BMS-986016) alone or in combination with nivolumab in recurrent or newly diagnosed GBM patients.